Aldridge quits Peplin

By Dylan Bushell-Embling
Tuesday, 19 August, 2008

US-incorporated biotech Peplin (ASX: PLI) has appointed BIO pioneer Tom Wiggans as CEO, replacing Michael Aldridge.

Wiggans, a former CEO of dermatology company Connetics, is also chairman of Peplin’s board of directors and will continue in that role.

Wiggans served on the board of directors of the US-based Biotechnology Industry Organisation (BIO) for 10 years.

Dr Eugene Bauer has been appointed both president and chief medical officer of the company, which recently re-incorporated in the US. Bauer served as CEO of Neosil Corporation, which recently entered into a merger agreement with Peplin.

Bauer will assume responsibility for the company’s medical affairs and strategies.

Peplin has also arranged to raise around $24 million in capital via a private share placement.

The money will primarily go towards funding of Phase III clinical trials of the company's PEP005 formulation.

PEP005 is an ingenol mebutate, intended as a treatment for actinic keratosis, a common pre-cancerous skin lesion.

Related News

Indigenous-led initiative to resurrect the South Island Giant Moa

New Zealand's Ngāi Tahu Research Centre has partnered with Colossal Biosciences and Sir Peter...

Abnormal brain protein targeted in Parkinson's study

Researchers have identified a new brain protein involved in the development of Parkinson's...

Epilepsy disease model treated in a laboratory dish

A research team has used an epilepsy-like disease model in a laboratory dish to demonstrate that...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd